Apical membrane antigen 1 (PfAMA1) (PfAMA1)

Apical membrane antigen 1 (PfAMA1) is a critical surface protein expressed by the Plasmodium falciparum parasite during the merozoite stage of its life cycle (UniProt: P04933). It plays a fundamental role in the invasion of host erythrocytes by facilitating the formation of a moving junction between the parasite and the red blood cell membrane, a process mediated through its interaction with the Rhoptry Neck Protein 2 (RON2) (PubMed: 21478870). The FVO (Falciparum Vietnam Okra) variant is a specific allelic form of PfAMA1 that has been extensively studied in vaccine development to address the high degree of genetic polymorphism found in wild parasite populations (PubMed: 15939659). Vaccines targeting this protein, such as AMA1-C1 or FMP2.1, aim to stimulate the host immune system to produce high titers of neutralizing antibodies that block the invasion process, thereby preventing the blood-stage infection that causes clinical malaria (PubMed: 21938215). Despite being highly immunogenic, the efficacy of PfAMA1-based vaccines has been limited by the parasite's ability to escape immune pressure through allelic variation, leading to a focus on multi-strain or conserved-epitope vaccine strategies (PubMed: 24550361). Current therapeutic approaches also explore the use of PfAMA1-RON2 complexes to elicit antibodies that target the essential binding interface more effectively.

Other names

AMA-1Apical membrane antigen 1PfAMA1-FVOMerozoite surface protein

Induction of host antibodies that block the interaction between PfAMA1 and RON2, preventing the formation of the moving junction and subsequent erythrocyte invasion.